Corvidia's series B round has been backed by Fresenius Medial Care and AstraZeneca as its kidney disease treatment nears the end of a phase 2 trial.
US-based precision therapy developer Corvidia Therapeutics closed a $60m series B round yesterday that featured kidney dialysis equipment provider Fresenius Medical Care and pharmaceutical firm AstraZeneca.
The deal was led by venture capital firm Venrock and also included Venrock’s Healthcare Capital Partners fund as well as Andera, Cormorant Asset Management, HBM Healthcare Investments, Apple Tree Partners and Sofinnova Partners.
Fresenius and AstraZeneca participated through corporate venturing unit Fresenius Medical Care Ventures and drug development subsidiary MedImmune respectively.
Corvidia is working…